Sermorelin: Sourcing, Documentation and Price

Sermorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), classified as a growth hormone-releasing hormone analogue and supplied as a research compound. It is also written as GRF 1-29 and GHRH(1-29)NH2, reflecting the 29-amino-acid amidated fragment of the native 44-residue GHRH. The evidence block used for this page does not supply a sequence string, molecular formula or molecular weight for sermorelin, so none is stated here; those values should be taken from the certificate of analysis accompanying a specific lot rather than from a general article. The work described below centres on the GHRH receptor and the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis.

Sermorelin appears in the peer-reviewed literature as one of the GHRH analogues encountered in the GH-IGF-1 axis category, alongside tesamorelin and the CJC-1295 variants, and alongside growth hormone secretagogues such as GHRP-2, GHRP-6, hexarelin and ipamorelin [1]. That categorisation matters for sourcing: the same review notes that peptides marketed as "research compounds" for performance purposes sit outside regulated pharmaceutical supply, which is the reason documentation quality varies so widely between vendors [1].

Research Studies

Sermorelin and the GHRH analogue class in GH-IGF-1 axis research

The primary published framing of sermorelin is taxonomic and pharmacological rather than trial-based. A review of performance-enhancing peptides that modulate the GH-IGF-1 axis lists sermorelin among the GHRH analogues most commonly encountered in clinical practice and in online self-administration protocols, together with tesamorelin, CJC-1295 with drug affinity complex (DAC) and CJC-1295 without DAC [1]. The same review groups the growth hormone secretagogues separately, and places the GH fragment AOD9604 (hGH 176-191) and IGF-1 analogues in their own categories [1]. For a laboratory buyer, the practical consequence is that sermorelin is defined by its receptor family — the GHRH receptor — and not by a body of controlled trial data of its own in this evidence set.

Sermorelin and the documentation problem in research-compound supply

The review cited above states directly that peptides marketed as research compounds for GH-IGF-1 modulation are unregulated [1]. That is the single most relevant fact for anyone assessing a supplier. It means identity, purity and quantity claims rest on the vendor's own analytical documentation rather than on any external approval. A buyer evaluating sermorelin should therefore treat the certificate of analysis, the lot number and the analytical method as the substantive product information, and treat marketing copy as non-evidentiary.

Tesamorelin and liver fat in adults with fatty liver disease

Because sermorelin and tesamorelin share the GHRH analogue class, tesamorelin trials are frequently used as the closest available clinical reference point for the class. A randomised, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin reduces liver fat in adults with fatty liver disease; participants receive tesamorelin or matching placebo for 52 weeks with standardised lifestyle counselling in both groups, liver fat is quantified by MRI-proton density fat fraction (MRI-PDFF), and safety monitoring includes glucose metrics and IGF-1 [2]. This is a tesamorelin study in a clinical population, not a sermorelin study, and it should not be read as evidence about sermorelin.

Tesamorelin and physical function in adults with HIV

A separate trial examines whether tesamorelin improves physical function and muscle health in adults with HIV when combined with exercise [3]. The rationale given is that people with HIV experience earlier impairments in physical function than the general population, show earlier and more rapid development of frailty, and respond less well to exercise alone [3]. Again, the population is adults with HIV and the compound is tesamorelin.

Tesamorelin and body composition in HIV lipodystrophy

A single-arm prospective study examines the effect of tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity, with body composition testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity assessment before, and at 6 and 12 months after, daily subcutaneous injections of tesamorelin 2 mg [6]. The design is single-arm, so it cannot isolate the drug effect from time or co-intervention.

Tesamorelin and nonalcoholic fatty liver disease with cardiovascular risk

A further study investigates whether tesamorelin reduces liver fat and liver inflammation in individuals with obesity and nonalcoholic fatty liver disease, on the stated basis that individuals with obesity on average secrete less growth hormone than individuals without obesity, and that growth hormone may reduce liver fat and inflammation [5]. The population is adults with obesity and NAFLD.

GHRH and cognitive function in mild cognitive impairment

GHRH itself, rather than a GHRH analogue, has been studied in mild cognitive impairment. One trial examines the effects of GHRH given at 1 mg/day for 10 weeks to subjects with mild cognitive impairment as well as healthy controls [7]. This is a GHRH study in a clinical population and is not evidence about sermorelin.

Octreotide and the GH-IGF-1 axis as a comparator direction

The axis can also be interrogated from the suppressive direction. A study of a new intranasal octreotide acetate formulation compares it with the approved subcutaneous formulation, evaluating safety and tolerability, absorption and elimination, and the ability of the drug to lower growth hormone and IGF-1 levels [8]. It is included here because it illustrates that GH-IGF-1 axis readouts — GH and IGF-1 — are the standard measurable endpoints in this field, and those are the endpoints a laboratory would typically quantify when characterising a GHRH analogue.

GHRH analogues and controlled ovarian stimulation protocols

GHRH-related pharmacology also appears in reproductive medicine. A trial evaluates a long Clomid protocol against a 5-day Clomid protocol for ovarian stimulation in patients with diminished ovarian reserve undergoing stimulation for in-vitro fertilisation, with the long protocol intended to intensify ovarian stimulation and reduce cost and injection burden; participants are randomised to the long Clomid protocol versus Clomid for 5 days followed by a GnRH antagonist, and the primary outcome is the number of mature eggs retrieved [4]. This concerns GnRH antagonism in a clinical fertility population and is not evidence about sermorelin.

Peptide signalling in orthopaedic tissue research

Broader therapeutic-peptide work reports that peptides act on signalling networks including PI3K/Akt, mTOR, MAPK, TGF-β and AMPK, and that this action influences tissue regeneration [9]. This is a general statement about peptide classes and is not specific to sermorelin or to the GHRH receptor.

Comparing the evidence base

Documentation to expect with a sermorelin lot

Given that the class is unregulated in the research-compound market [1], the documentation package is the product. A laboratory buyer should expect, at minimum:

• A lot-specific certificate of analysis stating identity and purity, with the analytical method named.
• A lot number that matches the label on the vial and the certificate.
• Storage and handling conditions stated for the specific lyophilised or reconstituted form.
• A stated quantity per vial, so that price can be normalised per milligram rather than per unit.

Where a vendor cannot supply a lot-matched certificate, the identity claim is unverifiable, and the review's observation that these compounds are marketed as research compounds outside regulated supply is the reason that risk exists [1].

Price factors

Price for a sermorelin lot is driven by the same variables as other research peptides: the quantity per vial, the purity specification, whether the lot is accompanied by lot-matched analytical documentation, and the cost of cold-chain handling where required. Because the market is unregulated [1], a lower headline price frequently reflects a thinner documentation package rather than a more efficient supply chain. The rational comparison is cost per milligram at a stated purity with a lot-matched certificate, not cost per vial. Our catalogue lists sermorelin as a 5 mg presentation; the certificate accompanying the specific lot is the authoritative source for its identity and purity values.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is a recommendation for human use.

Sources

• [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — https://europepmc.org/article/PMC/PMC13322892
• [2] Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) — https://clinicaltrials.gov/study/NCT07481734
• [3] Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV — https://clinicaltrials.gov/study/NCT06554717
• [4] Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation — https://clinicaltrials.gov/study/NCT06701071
• [5] Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk — https://clinicaltrials.gov/study/NCT03375788
• [6] Body Composition and Adipose Tissue in HIV — https://clinicaltrials.gov/study/NCT03226821
• [7] The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment — https://clinicaltrials.gov/study/NCT02553603
• [8] Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers — https://clinicaltrials.gov/study/NCT03031535
• [9] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — https://europepmc.org/article/PMC/PMC12753158